Capricor Therapeutics Inc (CAPR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $9.06 (-3.82%), Market cap $1.67B, 52-week low–high $4.60 ~ $35.34.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages
Financial statements, price targets, institutional (13F) holdings and related news for Capricor Therapeutics Inc are updated in real time on BlackAll Trade.
Capricor Therapeutics Inc trades at $9.06 (-3.82%). Real-time quotes and charts are available on BlackAll Trade.
Capricor Therapeutics Inc has a market cap of about $1.67B.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and